ASTELLAS PHARMA EUROPE B.V.

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Osteoarthritis of the Knee
Chronic Lower Back Pain

Interventions: Drug: ASP7962
Drug: Placebo
Drug: Naproxen

First Posted Date: 2015-11-20

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 215

Registration Number: NCT02611466

Locations: 🇭🇺
Site HU36002, Baja, Hungary
🇨🇿
Site CZ42006, Hradec Kralove, Czechia
🇧🇪
Site BE32003, Leuven, Belgium

and more 31 locations

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Phase 1

Completed

Conditions: Neurogenic Detrusor Overactivity
Overactive Bladder

Interventions: Drug: mirabegron

First Posted Date: 2015-08-18

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 9

Registration Number: NCT02526979

Locations: 🇵🇱
Site PL48001, Warsaw, Poland
🇩🇰
Site DK45002, Aalborg, Denmark
🇩🇰
Site DK45001, Aarhus, Denmark

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Pilocarpine
Drug: Placebo

First Posted Date: 2015-05-18

Last Posted Date: 2015-08-13

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 12

Registration Number: NCT02447315

Locations: 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom

First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ASP6282
Drug: Placebo
Drug: Pilocarpine
Drug: Itraconazole
Drug: Midazolam

First Posted Date: 2015-04-20

Last Posted Date: 2016-07-01

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 116

Registration Number: NCT02420782

Locations: 🇬🇧
Site GB44001, Harrow, United Kingdom
🇩🇪
Site DE49001, Berlin, Germany

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Phase 1

Completed

Conditions: Pharmacodynamics of ASP1707
Pharmacokinetics of ASP1707

Interventions: Drug: ASP1707 multiple dose of dose levels 1-4
Drug: ASP1707 parallel multiple dose of dose levels 1-3
Drug: ASP1707 single dose of dose levels 1 -7
Drug: Placebo single dose of dose levels 1-7
Drug: ASP1707 single dose fasted
Drug: ASP1707 single dose fed
Drug: Placebo multiple dose of dose levels 1-4
Drug: Placebo multiple dose of dose levels 1-2
Drug: ASP1707 multiple dose of dose levels 1-2
Drug: Placebo parallel multiple dose

First Posted Date: 2015-02-23

Last Posted Date: 2015-02-23

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 176

Registration Number: NCT02368912

Locations: 🇫🇷
SGS Life Science Services, Aster, Paris, France

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ASP6858
Drug: Placebo

First Posted Date: 2015-02-09

Last Posted Date: 2016-06-21

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 88

Registration Number: NCT02359032

Locations: 🇬🇧
Site GB44001, Harrow, United Kingdom

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Phase 2

Completed

Conditions: Chronic Kidney Disease
Type 2 Diabetes

Interventions: Drug: Placebo
Drug: ASP8232

First Posted Date: 2015-02-06

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 125

Registration Number: NCT02358096

Locations: 🇨🇿
Site CZ42003, Ceské Budejovice, Czechia
🇨🇿
Site CZ42002, Brno, Czechia
🇨🇿
Site CZ42001, Prague 4, Czechia

and more 54 locations

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Phase 1

Terminated

Conditions: Pharmacokinetics of ASP2205
Healthy Subjects

Interventions: Drug: ASP2205
Drug: Placebo

First Posted Date: 2014-12-11

Last Posted Date: 2016-06-21

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 93

Registration Number: NCT02314793

Locations: 🇬🇧
Site GB44001, Harrow, United Kingdom

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

Phase 2

Completed

Conditions: Diabetes Mellitus
Diabetic Macular Edema

Interventions: Drug: ASP8232
Drug: ranibizumab
Drug: Placebo
Other: Sham intravitreal (IVT) injection

First Posted Date: 2014-11-26

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 96

Registration Number: NCT02302079

Locations: 🇺🇸
Site US10021, Phoenix, Arizona, United States
🇺🇸
Site US10004, Beverly Hills, California, United States
🇺🇸
Site US10030, McAllen, Texas, United States

and more 18 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects

Phase 1

Withdrawn

Conditions: Pharmacokinetics of ASP3700
Healthy Volunteers

Interventions: Drug: Placebo
Drug: ASP3700

First Posted Date: 2014-11-07

Last Posted Date: 2015-01-12

Lead Sponsor: Astellas Pharma Europe B.V.

Registration Number: NCT02285465

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy